Replies to post #197120 on Biotech Values

[DewDiligence]

BIIB/Samsung—CHMP approves first EU FoB for Enbrel:

http://finance.yahoo.com/news/biogen-announces-benepali-etanercept-first-121500040.html

See #msg-118427495 for details of the Samsung Bioepsis partnerships with BIIB and MRK.

[DewDiligence]

Samsung Bioepis partners Rituxan FoB with AZN:

http://www.theinvestor.co.kr/view.php?ud=20161122000905

[DewDiligence]

CHMP approves Samsung-Bioepis/BIIB’s Enbrel FoB:

http://www.businesswire.com/news/home/20151120005300/en/Samsung-Bioepis-Receives-Positive-CHMP-Opinion-Etanercept

The is the first Enbrel FoB in the EU. BIIB has the marketing rights to this product in the EU, Japan, and Switzerland.

This product will not be commercialized in the US due to AMGN's long-running US Enbrel patent.

Note: The EU does not have a provision for approving interchangeable FoBs.

[DewDiligence]

MRK terminates FoB collaboration with Samsung Bioepis—takes $420M charge against 3Q18 earnings. (See fourth paragraph of PR in #msg-144445510.)